Vanda Pharmaceuticals and AnaptysBio have announced an exclusive worldwide licence agreement to develop and commercialise the fully humanised immunoglobulin G4 (IgG4) antibody, imsidolimab ...

The licensing agreement, announced Monday, gives Vanda (NASDAQ: VNDA) global and exclusive rights to market imsidolimab. San Diego-based AnaptysBio Inc. (NASDAQ: ANAB) handled the drug's research ...

ANAB remains risky despite new clinical data and partnerships; past successes haven't been replicated, and management's transparency issues raise concerns.

AnaptysBio announced an exclusive global license agreement with Vanda Pharmaceuticals for imsidolimab, which includes financial incentives, enhancing the company's revenue opportunities and ...

Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) and Anaptys Here is how AnaptysBio, Inc. (ANAB) and Inspire Medical Systems (INSP) have performed compared to their sector so far this year.

AnaptysBio may have ended last year on a low ... from its immuno-oncology partnership with GSK. Earlier this month, Vanda Pharmaceuticals agreed to pay $10 million upfront for the license to ...

Imsidolimab. In February 2025, Vanda announced it entered into an exclusive global license agreement with AnaptysBio Anaptys for the development and commercialization of imsidolimab that is an IL ...

Ratings for AnaptysBio ANAB were provided by 8 analysts in the past three months, showcasing a mix of bullish and bearish perspectives. Summarizing their recent assessments, the table below ...

Announced rosnilimab, a PD-1 depleter and agonist, achieved positive results from Phase 2b rheumatoid arthritis (RA) trial and highest-ever ...

our BDCA2 modulator Announced exclusive global license agreement with Vanda Pharmaceuticals to develop and commercialize imsidolimab, an IL-36R antagonist Year-end 2024 cash and investments of ~$ ...